Summary by Moomoo AI
Shanghai Fuxing Pharmaceuticals (Group) Co., Ltd. (abbreviated as “Fuxing Pharmaceuticals”) has issued its first quarter report for 2024. The report showed that for the three months ended 31 March 2024, the company's operating income was RMB101.57 billion, down 6.56% year-on-year; net profit attributable to shareholders of listed companies was RMB6.10 billion, down 38.22% year-on-year; basic earnings per share were $0.23, down 37.84% year-on-year. The decrease in sales revenue was mainly driven by sales of new crown-related products in the first quarter of 2023, while revenue from these products declined significantly for the same period in 2024. During the reporting period, non-recurring loss amounted to RMB0.01 billion, down year-on-year. In addition, the Company lifted the restricted sale of restricted A shares on January 9, 2024 and approved a share repurchase plan on March 26, 2024. As of the date of publication of the report, the Company has not repurchased shares. Major financial data and changes in financial indicators for Resusstar Pharmaceuticals have been published and have not been audited.
